欧洲泌尿外科学会(The European Association of Urology,EAU)2013年发表了新的《EAU男性性功能障碍指南(2013年版)》(以下简称《指南》)。在ED和PE的流行病学、诊断、治疗等方面做了论述。本文通过对《指南》中PDE5i解读,旨在帮助全科...欧洲泌尿外科学会(The European Association of Urology,EAU)2013年发表了新的《EAU男性性功能障碍指南(2013年版)》(以下简称《指南》)。在ED和PE的流行病学、诊断、治疗等方面做了论述。本文通过对《指南》中PDE5i解读,旨在帮助全科医生更加合理应用PDE5i。展开更多
目的探讨负压助勃装置联合PDE5i药物治疗勃起功能障碍患者的临床效果。方法选择2018年5月至2019年6月本院收治的勃起功能障碍患者200例作为研究对象,按照随机数字法分为对照组(n=100)和观察组(n=100)。对照组单用PDE5i药物治疗,观察组...目的探讨负压助勃装置联合PDE5i药物治疗勃起功能障碍患者的临床效果。方法选择2018年5月至2019年6月本院收治的勃起功能障碍患者200例作为研究对象,按照随机数字法分为对照组(n=100)和观察组(n=100)。对照组单用PDE5i药物治疗,观察组在对照组基础上联合负压助勃装置治疗,两组均治疗1个月。比较两组IIEF-5评分、阴茎长度及周径变化、患者及性伴侣满意度、安全性。结果两组治疗后1个月IIEF-5评分低于治疗后10 d(P<0.05);两组治疗后1个月阴茎长度及周径均长于治疗后10 d(P<0.05);观察组治疗后1个月、治疗后10 d IEF-5评分低于对照组(P<0.05);阴茎长度及周径均长于对照组(P<0.05);200例患者治疗后患者满意190例,满意率为95.00%,性伴侣满意194例,满意度为97.00%,患者治疗过程中均未发生阴茎麻木、不适应进行交痛等不良反应;超声下患者治疗后阴茎动脉血流峰值流速明显增加;部分患者尿道海绵体扩张。结论负压助勃装置联合PDE5i药物治疗勃起功能障碍能改善患者勃起功能,提高性生活满意度,且该治疗方法安全性较高,值得推广应用。展开更多
Erectile dysfunction(ED)is a common male disorder.Although orally-administered phosphodiesterase type 5 inhibitors(PDE5 inhibitors)are now recognized as the primary pharmacological treatment method for ED,20%-30%of th...Erectile dysfunction(ED)is a common male disorder.Although orally-administered phosphodiesterase type 5 inhibitors(PDE5 inhibitors)are now recognized as the primary pharmacological treatment method for ED,20%-30%of the patients treated with PDE5 inhibitors exhibit no significant effects.This study aims to investigate the influencing factors of ED in young adults with no response to PDE5 inhibitors.ED patients who would take PDE5 inhibitors were included and investigated with a questionnaire.Patients with no response to PDE5 inhibitors(tadalafil and sildenafil)served as study group,and those with response to PDE5 inhibitors as control group.Then Chi square test and logistic regression analysis were applied to find the potential influencing factors.In total,378 ED patients were included.Ninety-three(24.6%)cases were non-responsive to PDE5 inhibitors,and the remaining 285(75.4%)responded to PDE5 inhibitors.In multiple logistic regression analysis,we found that history of drinking(OR=3.152;95%CI 1.672-6.975),spousal noncooperation(OR=2.994;95%CI 1.589-5.638),number of fixed sex partners(OR=0.358;95%CI 0.132-0.651),duration of ED(OR=3.356;95%CI 1.352-8.333),and depression(OR=3.689;95%CI 1.579-8.979)could be the influencing factors for ED patients’non-response to PDE5 inhibitors.In conclusion,history of drinking,spousal noncooperation,number of fixed sex partner,long duration of ED,and depression could be the influencing factors for ED patients'non-response to PDE5 inhibitors.Patients and doctors should pay attention to these factors.展开更多
Erectile dysfunction(ED)is a common condition affecting men worldwide.The U.S.Food and Drug Administration(FDA)has approved phosphodiesterase type 5 inhibitors(PDE5Is),including sildenafil,tadalafil,vardenafil,and ava...Erectile dysfunction(ED)is a common condition affecting men worldwide.The U.S.Food and Drug Administration(FDA)has approved phosphodiesterase type 5 inhibitors(PDE5Is),including sildenafil,tadalafil,vardenafil,and avanafil,for treating ED.However,real-world studies on adverse events(AEs)linked to PDE5Is are limited.This study comprehensively assessed the safety of PDE5Is based on reports from the FDA adverse event reporting system(FAERS)database from January 2004 to June 2024.The disproportionality analysis was used to evaluate the safety profiles of PDE5Is.Based on demographic stratification,correlational analysis and signal differences examination in subgroups were performed in different PDE5Is.Among the 53517 AEs reports collected from the FAERS database,we identified 135,73,72,and 7 preferred terms associated with sildenafil,tadalafil,vardenafil,and avanafil,respectively.The study detected AEs listed on the FDA-approved label of each PDE5I.However,some AEs not listed on the labels were also identified.Some AEs listed by the FDA for PDE5Is were insignificant signals in our analysis.Significant differences were found among PDE5Is across age,weight,and onset time categories.We detected AEs related to the nervous,cardiovascular,and ocular systems that were not listed on the labels of the four PDE5Is,warranting further research on the underlying mechanisms.Additionally,significant differences in PDE5I-associated AEs were observed across age,weight,and onset time,highlighting the need for tailored patient management.展开更多
Icariin is a pure compound derived from Epimedium brevicornu Maxim,and it helps the regulation of male reproduction.Nevertheless,the role and underlying mechanisms of Icariin in mediating male germ cell development re...Icariin is a pure compound derived from Epimedium brevicornu Maxim,and it helps the regulation of male reproduction.Nevertheless,the role and underlying mechanisms of Icariin in mediating male germ cell development remain to be clarified.Here,we have demonstrated that Icariin promoted proliferation and DNA synthesis of mouse spermatogonial stem cells(SSCs).Furthermore,surface plasmon resonance iron(SPRi)and molecular docking(MOE)assays revealed that phosphodiesterase 5A(PDE5A)was an important target of Icariin in mouse SSCs.Mechanically,Icariin decreased the expression level of PDE5A.Interestingly,hydrogen peroxides(H2O2)enhanced the expression level of phosphorylation H2A.X(p-H2A.X),whereas Icariin diminished the expression level of p-H2A.X and DNA damage caused by H2O2 in mouse SSCs.Finally,our in vivo animal study indicated that Icariin protected male reproduction.Collectively,these results implicate that Icariin targets PDE5A to regulate mouse SSC viability and DNA damage and improves male reproductive capacity.This study thus sheds new insights into molecular mechanisms underlying the fate decisions of mammalian SSCs and offers a scientific basis for the clinical application of Icariin in male reproduction.展开更多
文摘欧洲泌尿外科学会(The European Association of Urology,EAU)2013年发表了新的《EAU男性性功能障碍指南(2013年版)》(以下简称《指南》)。在ED和PE的流行病学、诊断、治疗等方面做了论述。本文通过对《指南》中PDE5i解读,旨在帮助全科医生更加合理应用PDE5i。
文摘目的探讨负压助勃装置联合PDE5i药物治疗勃起功能障碍患者的临床效果。方法选择2018年5月至2019年6月本院收治的勃起功能障碍患者200例作为研究对象,按照随机数字法分为对照组(n=100)和观察组(n=100)。对照组单用PDE5i药物治疗,观察组在对照组基础上联合负压助勃装置治疗,两组均治疗1个月。比较两组IIEF-5评分、阴茎长度及周径变化、患者及性伴侣满意度、安全性。结果两组治疗后1个月IIEF-5评分低于治疗后10 d(P<0.05);两组治疗后1个月阴茎长度及周径均长于治疗后10 d(P<0.05);观察组治疗后1个月、治疗后10 d IEF-5评分低于对照组(P<0.05);阴茎长度及周径均长于对照组(P<0.05);200例患者治疗后患者满意190例,满意率为95.00%,性伴侣满意194例,满意度为97.00%,患者治疗过程中均未发生阴茎麻木、不适应进行交痛等不良反应;超声下患者治疗后阴茎动脉血流峰值流速明显增加;部分患者尿道海绵体扩张。结论负压助勃装置联合PDE5i药物治疗勃起功能障碍能改善患者勃起功能,提高性生活满意度,且该治疗方法安全性较高,值得推广应用。
文摘Erectile dysfunction(ED)is a common male disorder.Although orally-administered phosphodiesterase type 5 inhibitors(PDE5 inhibitors)are now recognized as the primary pharmacological treatment method for ED,20%-30%of the patients treated with PDE5 inhibitors exhibit no significant effects.This study aims to investigate the influencing factors of ED in young adults with no response to PDE5 inhibitors.ED patients who would take PDE5 inhibitors were included and investigated with a questionnaire.Patients with no response to PDE5 inhibitors(tadalafil and sildenafil)served as study group,and those with response to PDE5 inhibitors as control group.Then Chi square test and logistic regression analysis were applied to find the potential influencing factors.In total,378 ED patients were included.Ninety-three(24.6%)cases were non-responsive to PDE5 inhibitors,and the remaining 285(75.4%)responded to PDE5 inhibitors.In multiple logistic regression analysis,we found that history of drinking(OR=3.152;95%CI 1.672-6.975),spousal noncooperation(OR=2.994;95%CI 1.589-5.638),number of fixed sex partners(OR=0.358;95%CI 0.132-0.651),duration of ED(OR=3.356;95%CI 1.352-8.333),and depression(OR=3.689;95%CI 1.579-8.979)could be the influencing factors for ED patients’non-response to PDE5 inhibitors.In conclusion,history of drinking,spousal noncooperation,number of fixed sex partner,long duration of ED,and depression could be the influencing factors for ED patients'non-response to PDE5 inhibitors.Patients and doctors should pay attention to these factors.
基金supported by the Sichuan Science and Technology Program number(No.2025YFHZ0212).
文摘Erectile dysfunction(ED)is a common condition affecting men worldwide.The U.S.Food and Drug Administration(FDA)has approved phosphodiesterase type 5 inhibitors(PDE5Is),including sildenafil,tadalafil,vardenafil,and avanafil,for treating ED.However,real-world studies on adverse events(AEs)linked to PDE5Is are limited.This study comprehensively assessed the safety of PDE5Is based on reports from the FDA adverse event reporting system(FAERS)database from January 2004 to June 2024.The disproportionality analysis was used to evaluate the safety profiles of PDE5Is.Based on demographic stratification,correlational analysis and signal differences examination in subgroups were performed in different PDE5Is.Among the 53517 AEs reports collected from the FAERS database,we identified 135,73,72,and 7 preferred terms associated with sildenafil,tadalafil,vardenafil,and avanafil,respectively.The study detected AEs listed on the FDA-approved label of each PDE5I.However,some AEs not listed on the labels were also identified.Some AEs listed by the FDA for PDE5Is were insignificant signals in our analysis.Significant differences were found among PDE5Is across age,weight,and onset time categories.We detected AEs related to the nervous,cardiovascular,and ocular systems that were not listed on the labels of the four PDE5Is,warranting further research on the underlying mechanisms.Additionally,significant differences in PDE5I-associated AEs were observed across age,weight,and onset time,highlighting the need for tailored patient management.
基金supported by the grants from the National Nature Science Foundation of China(No.32170862)Developmental Biology and Breeding(No.2022XKQ0205)+2 种基金the Research Team for Reproduction Health and Translational Medicine of Hunan Normal University(No.2023JC101)Graduate Scientific Research Innovation Project of Hunan Province(No.CX2022520)Shanghai Key Laboratory of Reproductive Medicine(2022SKLRM01).
文摘Icariin is a pure compound derived from Epimedium brevicornu Maxim,and it helps the regulation of male reproduction.Nevertheless,the role and underlying mechanisms of Icariin in mediating male germ cell development remain to be clarified.Here,we have demonstrated that Icariin promoted proliferation and DNA synthesis of mouse spermatogonial stem cells(SSCs).Furthermore,surface plasmon resonance iron(SPRi)and molecular docking(MOE)assays revealed that phosphodiesterase 5A(PDE5A)was an important target of Icariin in mouse SSCs.Mechanically,Icariin decreased the expression level of PDE5A.Interestingly,hydrogen peroxides(H2O2)enhanced the expression level of phosphorylation H2A.X(p-H2A.X),whereas Icariin diminished the expression level of p-H2A.X and DNA damage caused by H2O2 in mouse SSCs.Finally,our in vivo animal study indicated that Icariin protected male reproduction.Collectively,these results implicate that Icariin targets PDE5A to regulate mouse SSC viability and DNA damage and improves male reproductive capacity.This study thus sheds new insights into molecular mechanisms underlying the fate decisions of mammalian SSCs and offers a scientific basis for the clinical application of Icariin in male reproduction.
